Valeant improves its offer for Allergan

After turning down previous unsolicited takeover offers by Valeant Pharmaceuticals, Allergan's board of directors has agreed to review a new proposal by the Canadian company which is due to expire on Aug. 15. The new offer would give Allergan's shareholders 0.83 Valeant shares and $72 in cash for each share ...

Keep reading this article by becoming a member


Enjoy unrestricted access to Eyewear Intelligence

To continue reading this article subscribe now

  • Unlimited access to our highly trusted industry insights and analysis
  • Benchmark yourself against the market and competitors
  • Find inspiration to drive your business forward
  • Stay up to date with new business models and startups

If you aren’t ready to subscribe now, you can REGISTER FOR FREE. Already an Eyewear Intelligence subscriber? Sign in here.